| Literature DB >> 29317795 |
Fanjing Meng1, Tingtao Chen1,2, Dongwen Ma1, Xin Wang2,3, Xiaoxiao Zhao1, Puyuan Tian1,2, Huan Wang1,3, Zhiwen Hai1, Liang Shen4, Xianyao Tang1, Xiaolei Wang1, Hongbo Xin1.
Abstract
Residues from herbal medicine processing in pharmaceutical plants create a large amount of waste (herb residues), which consists mainly of environmental pollution and medicinal waste. In order to resolve this problem, probiotics of Bacillus (B.) subtilis, Aspergillus (A.) oryzae, and Lactobacillus (L.) plantarum M3 are selected to reuse herb residue of Jianweixiaoshi tablets (JT), and an antibiotic-associated diarrhea (AAD) mouse model was established to evaluate the therapeutic effects of the herb residue fermentation supernatant. Our results indicated that the fermentation supernatant had scavenged 77.8% of 2,2-diphenyl-1-picrylhydrazyl (DPPH), 78% of O2•-, 36.7% of •OH, 39% of Fe2+ chelation, and 716 mg/L reducing power. The inhibition zones for Salmonella (S.) typhimurium, S. enteritidis, Shigella (Sh.) flexneri, Escherichia (E.) coli, Listeria (L.) monocytogenes, Sh. dysenteriae 301, and Staphylococcus (S.) aureus were 17, 14, 19, 18, 20, 19, and 20 mm, respectively. The in vivo results indicated that the fermentation supernatant resulted in a high diarrhea inhibition rate (56%, p < 0.05), greatly enhanced the disruption of bacterial diversity caused by antibiotics, and restored the dominant position of L. johnsonii in the treatment and recovery stages. Therefore, the combination of the herb residue and probiotics suggests a potential to explore conversion of these materials for the possible development of therapies for AAD.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29317795 PMCID: PMC5727800 DOI: 10.1155/2017/4265898
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Antioxidative (a) and antibacterial activity (b) of fermentation supernatant against selected foodborne pathogens compared with the control group (the herb residues). Data are shown as the mean ± SD. ∗p < 0.05.
The effects of fermentation supernatant on the diarrhea of mice.
| Groups | Total diarrhea frequency | Average diarrhea frequency | Ratio of diarrhea (%) | Inhibition ratio of diarrhea (%) |
|---|---|---|---|---|
| Modeling group | 72 | 7.2 ± 0.31 | 78 ± 2.67 | / |
| Probiotics + drug residues group | 32 | 3.2 ± 0.23∗ | 39 ± 1.24∗ | 56 |
| JT group | 58 | 5.8 ± 0.24∗ | 61 ± 2.31∗ | 19 |
Note: data are shown as the mean ± SD. ∗p < 0.05 (compared with the modeling group).
Figure 2DGGE profile and UPGMA analysis of the fecal microbiota using bacterial primers. (a, b, c) refer to the modeling group, probiotics + drug residues group, and JT group; L1–L3 from the control stage, L4–L6 from the modeling stage, L7–L9 from the treatment stage, and L4–L6 from recovery stage. The corresponding strains were seen in Table 2.
Strains identified from mouse intestine by denaturing gradient gel electrophoresis using bacterial primers and bacillus primers.
| Strain number | Closest relatives | Similarity (%) | GeneBank number |
|---|---|---|---|
|
| |||
| a |
| 100 | AB602933.1 |
| b | Uncultured bacterium | 100 | HQ321987.1 |
| c | Uncultured bacterium | 100 | GQ001435.1 |
| d | Uncultured | 100 | EF698450.1 |
| e |
| 100 | CP002464.1 |
| f |
| 100 | GU902714.1 |
| g | Uncultured | 100 | HM442510.1 |
| h |
| 100 | AB627080.1 |
| i | Uncultured bacterium | 100 | EU505174.1 |
| j | Uncultured bacterium | 100 | EU656086.1 |
| k |
| 100 | JF910016.1 |
| m | Uncultured bacterium | 100 | GU606372.1 |
| n | Uncultured bacterium | 100 | JF837882.1 |
|
| |||
| a | Uncultured bacterium | 100 | HM363549.1 |
| b |
| 100 | CP002464.1 |
| c | Uncultured bacterium | 99 | HM363550.1 |
| d | Uncultured bacterium | 100 | FJ881122.1 |
| e |
| 99 | Y10584.1 |
| f | Uncultured bacterium | 100 | EU006396.1 |
| g | Uncultured bacterium | 100 | EU475615.1 |
| h |
| 100 | HQ384298.1 |
| i | Uncultured bacterium | 100 | EU491355.1 |
| j | Uncultured bacterium | 100 | EU006313.1 |
Figure 3DGGE profile and UPGMA analysis of the fecal microbiota using bacillus primers. (a, b, c) refer to the modeling group, probiotics + drug residues group, and JT group; L1–L3 from the control stage, L4–L6 from the modeling stage, L7–L9 from the treatment stage, and L4–L6 from the recovery stage. The corresponding strains were seen in Table 2.